1423 POSTER Polymorphism Analysis in the AVADO Randomised Phase III Trial of First-line Bevacizumab (BEV) Combined With Docetaxel in HER2-negative Metastatic Breast Cancer (mBC)
作者
D.W. Miles,Sanne Lysbet de Haas,Gilles Romieu,Alfred A. Chan,Luc Dirix,Javier Cortés,Paul Delmar,S.J. Scherer